6794 Stock Overview
UnicoCell Biomed Co., Ltd. engages in the research and development of stem cell drugs, cell therapy technology, and regenerative medical services in Taiwan.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
UnicoCell Biomed Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$88.60 |
| 52 Week High | NT$104.00 |
| 52 Week Low | NT$68.00 |
| Beta | -0.31 |
| 1 Month Change | 1.61% |
| 3 Month Change | -1.56% |
| 1 Year Change | 15.36% |
| 3 Year Change | 131.03% |
| 5 Year Change | n/a |
| Change since IPO | 92.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6794 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 4.2% | 1.6% | 2.8% |
| 1Y | 15.4% | -24.5% | 27.4% |
Return vs Industry: 6794 exceeded the TW Biotechs industry which returned -24.5% over the past year.
Return vs Market: 6794 underperformed the TW Market which returned 27.4% over the past year.
Price Volatility
| 6794 volatility | |
|---|---|
| 6794 Average Weekly Movement | 3.5% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in TW Market | 8.7% |
| 10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 6794 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6794's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | n/a | www.unicocell.com |
UnicoCell Biomed Co., Ltd. engages in the research and development of stem cell drugs, cell therapy technology, and regenerative medical services in Taiwan. It develops ELIXCYTE, which is in Phase 2 clinical trials for the treatment of osteoarthritis and chronic kidney disease. The company offers UnicoVial, a cryotube and drug container for cell therapy products, as well as provides testing services.
UnicoCell Biomed Co., Ltd. Fundamentals Summary
| 6794 fundamental statistics | |
|---|---|
| Market cap | NT$4.93b |
| Earnings (TTM) | -NT$84.11m |
| Revenue (TTM) | NT$24.59m |
200.6x
P/S Ratio-58.7x
P/E RatioIs 6794 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6794 income statement (TTM) | |
|---|---|
| Revenue | NT$24.59m |
| Cost of Revenue | NT$6.69m |
| Gross Profit | NT$17.90m |
| Other Expenses | NT$102.01m |
| Earnings | -NT$84.11m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.51 |
| Gross Margin | 72.78% |
| Net Profit Margin | -342.06% |
| Debt/Equity Ratio | 0% |
How did 6794 perform over the long term?
See historical performance and comparison